'Why we do What we do in Cardiology'

These are the key points from this 2023 ACC/AHA guideline in managing chronic coronary disease. Patients with chronic coronary disease should receive care from a team of healthcare professionals ( Team-based, patient-centered care ) All patients with chronic coronary disease should be encouraged to make healthy lifestyle changes (nonpharmacologic therapies). Patients with chronic coronary disease...

The ATTRibute-CM trial was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial enrolled 632 patients with symptomatic ATTR-CM. Patients were randomly assigned to receive either acoramidis 800 mg twice daily or a placebo for 30 months. The trial's primary endpoint was...

Key Points from ARREST trial findings: The study included 862 patients who were resuscitated after a cardiac arrest. The patients were randomly assigned to be taken to either a well-resourced cardiac arrest center or the nearest emergency department. The primary outcome of the study was survival to 30 days. The secondary outcome was survival to 90 days. There was no difference in the survival rate...

Here is a summary of the key points from the 2023 ESC guidelines for the management of endocarditis: Prevention:  People at high risk of endocarditis should take steps to prevent it, such as taking antibiotics before dental procedures. Diagnosis:  The diagnosis of endocarditis is based on a combination of clinical features, blood cultures, and imaging studies. Antimicrobial therapy:  The duration...

This review highlights the following points: There are different ways to prevent blood clots in patients who have undergone LAAO for atrial fibrillation (AF). Taking a direct oral anticoagulant (DOAC) alone is associated with a lower risk of blood clots in the device and death than not taking any antithrombotic medication. For patients who are not at high risk of bleeding, taking a DOAC alone is l...

The review article was published in the Journal of the American College of Cardiology in August 2023 and was co-authored by Dr. Kyle Nelson, Dr. Valentin Fuster, and Dr. Paul Ridker. The review found that low-grade systemic inflammation, as determined by hsCRP, is a more powerful determinant of recurrent cardiovascular events, cardiovascular death, and all-cause mortality than low-density lipoprot...

LM CAD treatment needs sophisticated decision-making. Recent clinical practice standards guide clinicians; however, treating individual individuals might be tough. Anatomy and physiology determine LM CAD manifestations. Recognizing the complexity of LM CAD, which rarely occurs alone and sometimes with multivessel disease, a treatment protocol using medical therapy alone or in combination with PCI...

Screening for Asymptomatic Carotid Artery Stenosis in the General Population: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force, published in JAMA on February 2, 2021.  Link for the article: https://jamanetwork.com/journals/jama/fullarticle/2775704

The understanding, diagnosis, and treatment options for transthyretin (TTR) amyloid is rapidly evolving. American Heart Association published a statement titled "Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association". I have tried to present the key elements of this article.  Link: https://www.ahajournals.org/doi/10.1161/CIR.000000000000...